CN110702921B - 用于诊断和预后肾损伤和肾衰竭的方法和组合物 - Google Patents
用于诊断和预后肾损伤和肾衰竭的方法和组合物 Download PDFInfo
- Publication number
- CN110702921B CN110702921B CN201910986041.5A CN201910986041A CN110702921B CN 110702921 B CN110702921 B CN 110702921B CN 201910986041 A CN201910986041 A CN 201910986041A CN 110702921 B CN110702921 B CN 110702921B
- Authority
- CN
- China
- Prior art keywords
- subject
- hours
- serum creatinine
- likelihood
- scr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000001647 Renal Insufficiency Diseases 0.000 title claims abstract description 12
- 201000006370 kidney failure Diseases 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title abstract description 89
- 206010061481 Renal injury Diseases 0.000 title abstract description 56
- 208000037806 kidney injury Diseases 0.000 title abstract description 48
- 239000000203 mixture Substances 0.000 title abstract description 10
- 238000003556 assay Methods 0.000 claims abstract description 73
- 102100023705 C-C motif chemokine 14 Human genes 0.000 claims abstract description 47
- 101710112614 C-C motif chemokine 14 Proteins 0.000 claims abstract description 47
- 238000003745 diagnosis Methods 0.000 claims abstract description 24
- 238000012544 monitoring process Methods 0.000 claims abstract description 22
- 238000004393 prognosis Methods 0.000 claims abstract description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 782
- 210000002700 urine Anatomy 0.000 claims description 437
- 229940109239 creatinine Drugs 0.000 claims description 391
- 210000002966 serum Anatomy 0.000 claims description 374
- 201000011040 acute kidney failure Diseases 0.000 claims description 114
- 230000003907 kidney function Effects 0.000 claims description 81
- 208000033626 Renal failure acute Diseases 0.000 claims description 76
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 47
- 210000001124 body fluid Anatomy 0.000 claims description 39
- 238000012959 renal replacement therapy Methods 0.000 claims description 38
- 210000004369 blood Anatomy 0.000 claims description 36
- 239000008280 blood Substances 0.000 claims description 36
- 210000003734 kidney Anatomy 0.000 claims description 32
- 239000002872 contrast media Substances 0.000 claims description 28
- 208000012998 acute renal failure Diseases 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 210000002381 plasma Anatomy 0.000 claims description 21
- 238000013517 stratification Methods 0.000 claims description 21
- 239000010839 body fluid Substances 0.000 claims description 19
- 230000002829 reductive effect Effects 0.000 claims description 15
- 230000024924 glomerular filtration Effects 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 238000002054 transplantation Methods 0.000 claims description 11
- 206010019280 Heart failures Diseases 0.000 claims description 8
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 6
- 206010062237 Renal impairment Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 231100000857 poor renal function Toxicity 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 229940126575 aminoglycoside Drugs 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 229930182912 cyclosporin Natural products 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000001554 Hemoglobins Human genes 0.000 claims description 4
- 108010054147 Hemoglobins Proteins 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 108010062374 Myoglobin Proteins 0.000 claims description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
- 238000007675 cardiac surgery Methods 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 229940093476 ethylene glycol Drugs 0.000 claims description 4
- 229960005102 foscarnet Drugs 0.000 claims description 4
- 229910001385 heavy metal Inorganic materials 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 201000011461 pre-eclampsia Diseases 0.000 claims description 4
- 201000001474 proteinuria Diseases 0.000 claims description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 4
- 229960001052 streptozocin Drugs 0.000 claims description 4
- 229960001967 tacrolimus Drugs 0.000 claims description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 4
- 208000002296 eclampsia Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims 8
- 229940039227 diagnostic agent Drugs 0.000 claims 8
- 238000011088 calibration curve Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000036675 Myoglobin Human genes 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 abstract description 44
- 101710192735 Tyrosine-protein kinase receptor UFO Proteins 0.000 abstract description 43
- 102100023700 C-C motif chemokine 16 Human genes 0.000 abstract description 39
- 101710112632 C-C motif chemokine 16 Proteins 0.000 abstract description 39
- 238000011269 treatment regimen Methods 0.000 abstract description 5
- 239000000104 diagnostic biomarker Substances 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 205
- 239000003550 marker Substances 0.000 description 189
- 230000002459 sustained effect Effects 0.000 description 147
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 76
- 230000006378 damage Effects 0.000 description 76
- 208000014674 injury Diseases 0.000 description 69
- 208000027418 Wounds and injury Diseases 0.000 description 67
- 238000011084 recovery Methods 0.000 description 66
- 230000002688 persistence Effects 0.000 description 57
- 230000007115 recruitment Effects 0.000 description 35
- 238000003018 immunoassay Methods 0.000 description 32
- 230000002085 persistent effect Effects 0.000 description 30
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 201000003068 rheumatic fever Diseases 0.000 description 30
- 229920001184 polypeptide Polymers 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 239000000090 biomarker Substances 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 230000006872 improvement Effects 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 201000010099 disease Diseases 0.000 description 24
- 238000005259 measurement Methods 0.000 description 23
- 230000001154 acute effect Effects 0.000 description 22
- 239000012491 analyte Substances 0.000 description 19
- 239000012071 phase Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000007423 decrease Effects 0.000 description 17
- 230000002485 urinary effect Effects 0.000 description 16
- 230000035945 sensitivity Effects 0.000 description 15
- 230000027455 binding Effects 0.000 description 13
- 208000020832 chronic kidney disease Diseases 0.000 description 13
- 238000000502 dialysis Methods 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 10
- 230000002596 correlated effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 239000007790 solid phase Substances 0.000 description 9
- -1 100% Chemical compound 0.000 description 8
- 208000015698 cervical squamous intraepithelial neoplasia Diseases 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000027939 micturition Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 208000017169 kidney disease Diseases 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000017667 Chronic Disease Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 201000000523 end stage renal failure Diseases 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000002250 progressing effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 108010036941 Cyclosporins Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000013519 Lipocalin-2 Human genes 0.000 description 4
- 108010051335 Lipocalin-2 Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 208000028208 end stage renal disease Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008085 renal dysfunction Effects 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000003066 decision tree Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940089988 hep-lock Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 201000006334 interstitial nephritis Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 101800001718 Amyloid-beta protein Proteins 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 208000023146 Pre-existing disease Diseases 0.000 description 2
- 229910001219 R-phase Inorganic materials 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000018614 Uromodulin Human genes 0.000 description 2
- 108010027007 Uromodulin Proteins 0.000 description 2
- 206010070995 Vascular compression Diseases 0.000 description 2
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940000489 arsenate Drugs 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 238000013130 cardiovascular surgery Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960002160 maltose Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000010024 tubular injury Effects 0.000 description 2
- 208000037978 tubular injury Diseases 0.000 description 2
- RFCQDOVPMUSZMN-UHFFFAOYSA-N 2-Naphthalenethiol Chemical compound C1=CC=CC2=CC(S)=CC=C21 RFCQDOVPMUSZMN-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 description 1
- 101710186701 Alpha-1-acid glycoprotein 1 Proteins 0.000 description 1
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 102000004149 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 101150064697 CXCL16 gene Proteins 0.000 description 1
- 101100360207 Caenorhabditis elegans rla-1 gene Proteins 0.000 description 1
- 108010028310 Calbindin 1 Proteins 0.000 description 1
- 102000016838 Calbindin 1 Human genes 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 1
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102100028007 Cystatin-SA Human genes 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 229940094664 Cysteine protease inhibitor Drugs 0.000 description 1
- 101710144510 Cysteine proteinase inhibitor Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 1
- 102100038002 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Human genes 0.000 description 1
- 101710133440 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 1
- 101710136552 Fatty acid-binding protein, heart Proteins 0.000 description 1
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 1
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 101710195403 Glutathione S-transferase P Proteins 0.000 description 1
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 1
- 101710112368 Glutathione S-transferase P 1 Proteins 0.000 description 1
- 101710112365 Glutathione S-transferase P 2 Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010073791 Glycine amidinotransferase Proteins 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102400000531 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000037862 Ion Transporter Human genes 0.000 description 1
- 108091006671 Ion Transporter Proteins 0.000 description 1
- 108010013792 Isovaleryl-CoA Dehydrogenase Proteins 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 102000016776 Midkine Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102100036836 Natriuretic peptides B Human genes 0.000 description 1
- 101710187802 Natriuretic peptides B Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
- 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 101150025379 RPA1 gene Proteins 0.000 description 1
- 101000999374 Rattus norvegicus Interferon-related developmental regulator 1 Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000223 Solitary Kidney Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000014456 Trefoil Factor-3 Human genes 0.000 description 1
- 108010078184 Trefoil Factor-3 Proteins 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000001801 Z-test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004082 amperometric method Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 108010014802 atrial natriuretic factor prohormone (1-98) Proteins 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 238000013531 bayesian neural network Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002665 bowman capsule Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000572 ellipsometry Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 108010057863 heparin receptor Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 229940118526 interleukin-9 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000000193 iodinated contrast media Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108091007169 meprins Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 231100000637 nephrotoxin Toxicity 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 230000009723 vascular congestion Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910986041.5A CN110702921B (zh) | 2014-10-20 | 2015-10-20 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066310P | 2014-10-20 | 2014-10-20 | |
| US201462066313P | 2014-10-20 | 2014-10-20 | |
| US201462066316P | 2014-10-20 | 2014-10-20 | |
| US62/066,316 | 2014-10-20 | ||
| US62/066,310 | 2014-10-20 | ||
| US62/066,313 | 2014-10-20 | ||
| CN201580068922.9A CN107003301B (zh) | 2014-10-20 | 2015-10-20 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| PCT/US2015/056462 WO2016064877A2 (en) | 2014-10-20 | 2015-10-20 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN201910986041.5A CN110702921B (zh) | 2014-10-20 | 2015-10-20 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580068922.9A Division CN107003301B (zh) | 2014-10-20 | 2015-10-20 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110702921A CN110702921A (zh) | 2020-01-17 |
| CN110702921B true CN110702921B (zh) | 2024-02-06 |
Family
ID=55761743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910986041.5A Active CN110702921B (zh) | 2014-10-20 | 2015-10-20 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| CN201580068922.9A Active CN107003301B (zh) | 2014-10-20 | 2015-10-20 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580068922.9A Active CN107003301B (zh) | 2014-10-20 | 2015-10-20 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11333671B2 (https=) |
| EP (2) | EP3210018B1 (https=) |
| JP (4) | JP6792553B2 (https=) |
| KR (1) | KR102431003B1 (https=) |
| CN (2) | CN110702921B (https=) |
| AU (2) | AU2015336069B2 (https=) |
| BR (1) | BR112017008218A2 (https=) |
| CA (1) | CA2965153C (https=) |
| EA (1) | EA201790696A1 (https=) |
| ES (1) | ES2907551T3 (https=) |
| MX (1) | MX388231B (https=) |
| PT (1) | PT3210018T (https=) |
| WO (1) | WO2016064877A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2965153C (en) | 2014-10-20 | 2023-10-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP4063853A1 (en) * | 2017-01-12 | 2022-09-28 | Astute Medical, Inc. | Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement |
| CN110431422A (zh) | 2017-02-06 | 2019-11-08 | 机敏医药股份有限公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US11891439B2 (en) | 2017-12-28 | 2024-02-06 | Astute Medical, Inc. | Antibodies and assays for CCL14 |
| US12114978B2 (en) | 2018-04-02 | 2024-10-15 | Potrero Medical, Inc. | Systems, devices and methods for draining and analyzing bodily fluids and assessing health |
| CN119454032A (zh) * | 2018-04-02 | 2025-02-18 | 波特雷罗医疗公司 | 用于排出和分析体液并评估健康的系统、设备和方法 |
| CN114207436A (zh) * | 2019-05-24 | 2022-03-18 | 机敏医药股份有限公司 | 基于c-c基序趋化因子配体14测量而评估和治疗肾损伤的方法 |
| US20230290457A1 (en) * | 2020-03-23 | 2023-09-14 | Biocogniv Inc. | Artificial intelligence medical device |
| GB2596142B (en) * | 2020-06-19 | 2023-11-29 | Secr Defence | Methods and associated uses, kits and systems for assessing sepsis |
| EP4247395A4 (en) * | 2020-11-18 | 2024-09-18 | Astute Medical, Inc. | Methods and compositions for treatment of renal injury and renal failure |
| CA3253529A1 (en) * | 2022-03-03 | 2023-09-07 | Astute Medical, Inc. | METHODS AND COMPOSITIONS FOR EVALUATING AND TREATING PERSISTENT ACUTE RENAL INJURY BASED ON A C-C MOTIFYING CHEMOKIN LIGAND MEASUREMENT 14 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725635A (zh) * | 2009-11-07 | 2012-10-10 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| CN103080743A (zh) * | 2010-06-23 | 2013-05-01 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| CN103167879A (zh) * | 2010-07-09 | 2013-06-19 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| WO2013096740A1 (en) * | 2011-12-21 | 2013-06-27 | Alere San Diego Inc. | Methods and compositions for assigning likelihood of chronic kidney disease progression |
| CN103534593A (zh) * | 2010-12-14 | 2014-01-22 | 詹姆斯·W·利拉德 | 抗cxcl16抗体和抗cxcr6抗体在治疗或检测癌症中的用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| AU1772992A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| JP3290988B2 (ja) | 1991-04-11 | 2002-06-10 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | 多重リガンドを同時検出する新規接合体及び検定法 |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6811773B1 (en) | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| AU2003223172A1 (en) | 2002-02-12 | 2003-09-04 | Quark Biotech, Inc. | Use of the axl receptor for diagnosis and treatment of renal disease |
| EP1915614A4 (en) | 2005-07-21 | 2009-03-25 | Univ Johns Hopkins | METHOD FOR DETECTING AND TREATING AN ACUTE KIDNEY INJURY |
| WO2007035843A2 (en) * | 2005-09-21 | 2007-03-29 | Dask Technologies, Llc | Methods and compositions for organ and tissue functionality |
| US20110059537A1 (en) | 2007-09-20 | 2011-03-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for estimating risk of acute kidney injury |
| WO2009114110A1 (en) | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| CA2740923A1 (en) * | 2008-10-21 | 2010-04-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2462437A4 (en) * | 2009-08-07 | 2013-01-30 | Rules Based Medicine Inc | METHOD AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISEASES THEREOF |
| CA2774223A1 (en) | 2009-09-21 | 2011-03-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ600160A (en) * | 2009-11-07 | 2014-05-30 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20120156701A1 (en) * | 2009-12-20 | 2012-06-21 | Joseph Anderberg | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2011075744A1 (en) | 2009-12-20 | 2011-06-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2011213684B2 (en) * | 2010-02-05 | 2014-11-20 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| IN2012MN02812A (https=) * | 2010-06-23 | 2015-05-22 | Astute Medical Inc | |
| WO2012136548A1 (en) | 2011-04-04 | 2012-10-11 | Universiteit Gent | Biomarkers for acute kidney injury |
| PT2748605T (pt) | 2011-08-26 | 2019-05-03 | Astute Medical Inc | Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal |
| US10935548B2 (en) * | 2011-12-08 | 2021-03-02 | Astute Medical, Inc. | Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2 |
| EP2962109A4 (en) | 2013-02-26 | 2016-12-07 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
| CA2965153C (en) | 2014-10-20 | 2023-10-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
-
2015
- 2015-10-20 CA CA2965153A patent/CA2965153C/en active Active
- 2015-10-20 EP EP15853584.9A patent/EP3210018B1/en active Active
- 2015-10-20 PT PT15853584T patent/PT3210018T/pt unknown
- 2015-10-20 KR KR1020177013539A patent/KR102431003B1/ko active Active
- 2015-10-20 AU AU2015336069A patent/AU2015336069B2/en active Active
- 2015-10-20 US US15/520,817 patent/US11333671B2/en active Active
- 2015-10-20 EP EP21186630.6A patent/EP3968022A1/en active Pending
- 2015-10-20 ES ES15853584T patent/ES2907551T3/es active Active
- 2015-10-20 MX MX2017005126A patent/MX388231B/es unknown
- 2015-10-20 BR BR112017008218A patent/BR112017008218A2/pt not_active Application Discontinuation
- 2015-10-20 WO PCT/US2015/056462 patent/WO2016064877A2/en not_active Ceased
- 2015-10-20 CN CN201910986041.5A patent/CN110702921B/zh active Active
- 2015-10-20 JP JP2017521231A patent/JP6792553B2/ja active Active
- 2015-10-20 EA EA201790696A patent/EA201790696A1/ru unknown
- 2015-10-20 CN CN201580068922.9A patent/CN107003301B/zh active Active
-
2020
- 2020-11-06 JP JP2020185705A patent/JP7002623B2/ja active Active
-
2021
- 2021-12-27 JP JP2021211779A patent/JP7217796B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201130A patent/AU2022201130B2/en active Active
- 2022-03-31 US US17/710,832 patent/US12099067B2/en active Active
-
2023
- 2023-01-24 JP JP2023008480A patent/JP2023052587A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725635A (zh) * | 2009-11-07 | 2012-10-10 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| CN103080743A (zh) * | 2010-06-23 | 2013-05-01 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| CN103167879A (zh) * | 2010-07-09 | 2013-06-19 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| CN103534593A (zh) * | 2010-12-14 | 2014-01-22 | 詹姆斯·W·利拉德 | 抗cxcl16抗体和抗cxcr6抗体在治疗或检测癌症中的用途 |
| WO2013096740A1 (en) * | 2011-12-21 | 2013-06-27 | Alere San Diego Inc. | Methods and compositions for assigning likelihood of chronic kidney disease progression |
Non-Patent Citations (5)
| Title |
|---|
| HCC-1, a Novel Chemokine from Human Plasma;Peter Schulz-Knappe等;J. Exp. Med;第483卷;摘要，第 298 页右栏第1段，图4 * |
| J J Haringman等.Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis,osteoarthritis, and reactive arthritis.《Ann Rheum Dis》.2005,第65卷第294-300页. * |
| Peter Schulz-Knappe等.HCC-1, a Novel Chemokine from Human Plasma.J. Exp. Med.1996,第483卷摘要，第 298 页右栏第1段，图4. * |
| Sik Lee等.Distinct Macrophage Phenotypes Contribute to Kidney Injury and Repair.《J Am Soc Nephrol》.2011,第22卷第317-326页. * |
| 毛建华.CC16：一种新的肾小管性蛋白尿的指标.《国外医学》.1997,第17卷(第2期), * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110702921B (zh) | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 | |
| HK1199931A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1212764A1 (zh) | 用於肾损伤和肾衰竭的诊断及预後的方法和组合物 | |
| HK1208074A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1200218A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1220764A1 (zh) | 肾损伤和肾衰竭的诊断及预後 | |
| HK1211084A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| CN107003325A (zh) | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 | |
| HK1204339A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1207155A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1232600A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1232600A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1236621A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1236620A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1212774B (en) | Methods and composition for diagnosis and prognosis of renal injury and renal failure | |
| HK1212774A1 (zh) | 用於腎損傷和腎衰竭的診斷及預後方法和組合物 | |
| HK1162617B (zh) | 腎損傷和腎衰竭的診斷和預後 | |
| HK1219129A1 (zh) | 用於肾损伤和肾衰竭的诊断及预後的方法和组合物 | |
| HK1167455A1 (zh) | 用於腎損傷和腎衰竭的診斷及預後方法和組合物 | |
| CN107735147A (zh) | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 | |
| HK1203620B (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1167455B (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1172691B (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1203620A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| HK1195128A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TG01 | Patent term adjustment | ||
| TG01 | Patent term adjustment |